CAR-T 細胞を使用した細胞療法中および免疫エフェクター細胞関連神経毒性症候群の発生中の細胞外小胞の時間的特徴付け (VESICANS)
Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a common and serious neurological complication associated with the use of CAR-T cells. The mechanisms involved are still poorly understood but studies suggest that inflammation during treatment leads to an increase in the permeability of the barrier between the brain and the blood vessels and the emission of extracellular vesicles (EVs) circulating between the brain and the blood vessels. EVs are biological particles that play an important role in cellular communication and the modulation of several physiological processes. The VESICANS study aims to characterize the EVs released before and during CAR-T cells treatment and upon the occurrence of ICANS, using flow cytometry, electron microscopy, Nanoparticle Tracking Analysis associated with MRI assessment of the barrier between the brain and blood. This study will ultimately contribute to facilitating the prevention and treatment of this toxicity which affects the prognosis of patients.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Emilie CHALAYER, MD
- 電話番号:+33 (0)4 77 82 28 14
- メール:emilie.chalayer@chu-st-etienne.fr
研究連絡先のバックアップ
- 名前:Hélène RAINGARD
- 電話番号:+33 (0)4 77 82 97 03
- メール:helene.raingard@chu-st-etienne.fr
研究場所
-
-
-
Saint-Etienne、フランス、42055
- 募集
- CHU de Saint-Etienne
-
副調査官:
- Ludovic FOUILLET, MD
-
副調査官:
- Emmanuelle TAVERNIER, MD
-
コンタクト:
- Emilie CHALAYER, MD
- 電話番号:33 (0)4 77 82 28 14
- メール:emilie.chalayer@chu-st-etienne.fr
-
副調査官:
- Jérôme CORNILLON, MD
-
副調査官:
- Manon SAPET, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient aged over 18,
- Patient for whom CAR-T treatment is indicated,
- Patient affiliated to a social security system
- Patient who give his consent to participate in the study.
Exclusion Criteria:
- Pregnant or breastfeeding woman,
- Patient unable to understand informed consent,
- Patient under legal protection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:CAR T cell treatment
Major patients for whom CAR-T treatment is indicated. |
Biological tests : cell quantification et characterization MRI Neuropsychological tests |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Endothelial EVs quantification (EVs/mL)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Quantification by Nano Tracking Analysis of endothelial EVs as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Endothelial EVs characterization (immunophenotyping)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization by Nano Tracking Analysis (immunophenotyping by size) of endothelial EVs as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Other EV subtypes quantification (EV subtype/mL)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Other EV subtypes quantification of as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Other EV subtypes characterization (immunophenotyping)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Other EV subtypes characterization of as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVS quantification according to the presence of an ICANS versus no ICANS (EV/mL)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVS quantification according to the presence of an ICANS versus no ICANS |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization according to the presence of an ICANS versus no ICANS (immunophenotyping)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVS characterization of EVs according to the presence of an ICANS versus no ICANS |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs quantification according to levels of cytokines (EVs/mL)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs quantification according to levels of cytokines |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization according to levels of cytokines
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs characterization according to levels of cytokines |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs quantification in cerebrospinal fluid (EVs/mL)
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs quantification after treatment with CAR-T cells in cerebrospinal fluid (CSF) if available. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization in cerebrosinalfluid.
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs characterization of EVs after treatment with CAR-T cells in cerebrospinal fluid (CSF) if available. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Association of EVs subpopulations in clinical neurological damage and sleep apnea syndrome.
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization of the association of subpopulations of EVs according to clinical neurological damage and sleep apnea syndrome. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Association of EVs subpopulations in neuropsychological test and RMI.
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization of the association of subpopulations of EVs according to neuropsychological test and RMI. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Cerabral involvement on RMI
時間枠:Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Diffusion tensor imaging and resting state default mode network |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
協力者と研究者
捜査官
- 主任研究者:Emilie CHALAYER, MD、Centre Hospitalier Universitaire de Saint Etienne
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。